

INDGN/SE/2026-27/53

23 September 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Subject: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the copy of Press Release dated September 23, 2026, titled "From Promise to Performance: Life Sciences Leaders Focus on Operationalizing AI to Deliver Enterprise Outcomes at Indegene Digital Summit 2026".

This will also be posted on the company's website at: <https://www.indegene.com/>

We request you to kindly take the same on record.

Thanking You

Yours Sincerely,
For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer

Encl: A/a



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
compliance.officer@indegene.com
www.indegene.com

CIN: L73100KA1998PLC102040

From Promise to Performance: Life Sciences Leaders Focus on Operationalizing AI to Deliver Enterprise Outcomes at Indegene Digital Summit 2026

VITAL Awards 2026 honored leaders advancing organizational and market impact, with special recognition for transformational leadership

Princeton, NJ, 23rd September 2026: Senior leaders of the life sciences industry convened for the eighth edition of the Indegene Digital Summit to exchange thoughts, insights and experiences of how organizations can translate AI investments into measurable business impact.

The invitation-only event, held on September 22 at the National Constitution Center in Philadelphia against the backdrop of the United States' 250th anniversary, brought together 200+ leaders from across the global life sciences ecosystem for candid, peer-led discussions without sales pitches or vendor noise. Dedicated to dialogue, leadership, and enduring ideas, the venue offered a fitting setting for conversations on the future of life sciences and the role of leaders in turning bold ideas into action.

This year's theme, "From Promise to Performance: Operationalizing AI for Enterprise Outcomes," focused on the industry's challenge of translating AI investment into business outcomes. The discussions examined why applying AI to operating models built for another era is insufficient, and what companies must change in the way work, data, decisions, content, governance, talent, and partnerships operate.

Speakers and participants explored customer engagement in 2028, the future of work, AI-enabled launch models, AI-native revenue maximization, and the connection between AI and profit-and-loss impact. Sessions also addressed changes in U.S. drug approval and pricing policy, point-of-care AI, the role of the chief digital and information officer in shaping pharma's AI agenda, and the digital capabilities and global operating models required to improve customer experience.

Featured speakers included David Shulkin, Ninth Secretary of the U.S. Department of Veterans Affairs; Amol Punjabi, Chief Product Officer, Open Evidence; Agam Upadhyay, SVP and Chief Digital & Information Officer, Vertex Pharmaceuticals; Corinne Le Goff, Chief Commercial Officer, Viatrix; Chumi Khurana, SVP, U.S. Oncology Franchise Head, Jazz Pharmaceuticals; Jeremy Shepler, VP, Commercial DAS Leader, J&J Innovative Medicine; Radife Kiral, CFC Capabilities and Commercial Excellence Lead, Pfizer; Kate Duffy, Marketing AI Product Lead, AIA, Pfizer; Madelene Glomsten, Head of Global Marketing, Sanofi; Saket Malhotra, Global Head of Commercial Digital, BioMarin Pharmaceutical Inc.; Shane Schaffer, CEO and Chairman, Cingulate Therapeutics; Shaan Gandhi, VP and Head of Partnerships PAVE, Pfizer; Steve Winawer, Sun Pharma; and Tarun Mathur, Chief Technology Officer, Indegene, among others.

Key themes that emerged from the presentations and discussions at the summit included a broad-based recognition that operationalizing AI for business impact requires a next generation, life-sciences native operating model powered by domain understanding, experience and context. Beyond operational efficiency, several life sciences leaders pointed out that AI can help connect data, intelligence and evidence to enable strategic decisions, drive successful product launches, deliver more personalized customer experiences and accelerate drug discovery and clinical research.

Speaking on the occasion, Manish Gupta, Chairman and CEO, Indegene said, "Life sciences has built an extraordinary legacy of helping people live longer, healthier lives. But increasingly specialized therapies and precision medicines cannot be supported by operating models designed for an era of mass promotion. The opportunity now is to thoughtfully rewire the enterprise around AI, augment our people, and build systems that are smarter, faster, and more responsive, turning the promise of technology into measurable performance for patients, physicians, and the business."

The VITAL Awards Recognize Leaders Shaping the Future of Life Sciences

The Summit also hosted the second edition of the VITAL Awards, recognizing life sciences leaders delivering measurable industry impact. Honorees were named across two jury-evaluated categories, Organizational Impact, and Market Impact, alongside special VITAL Awards for Transformational Leadership.

Organizational Impact: Leaders driving meaningful change within their organizations through new operating models, capabilities, collaboration, technology adoption, or ways of working.

Market Impact: Leaders delivering measurable market impact through launch strategy, commercialization models, customer engagement, portfolio growth, or operational execution.

Nominations in the impact categories were evaluated for innovation, measurable impact, and leadership by a cross-disciplinary jury spanning life sciences, healthcare, research, media, and industry leadership. The jury included:

- Jill DeSimone, former U.S. Head of Oncology, Merck
- David Shulkin, Ninth Secretary, U.S. Department of Veterans Affairs
- Michelle Keefe, former CEO, Syneos Health
- Aida Habtezion, former Chief Medical Officer, Pfizer
- Rohan Kulkarni, Executive Research Leader, HFS Research
- Jameson Fleming, former Chief Editor, MM+M
- Dr. Rajesh Nair, President, Indegene, Inc.

VITAL Awards 2026 Honorees

Transformational Leadership: Brian Cantwell, VP, Head of AI, US Pharma, Bayer; and Agam Upadhyay, SVP, Chief Digital and Information Officer, Vertex.

Organizational Impact: Amanda Marvel, Senior Marketing Director, Gilead Sciences; and Saket Malhotra, Global Head of Commercial Digital, BioMarin.

Market Impact: Lauren Jones, Head of Digital Marketing, Incyte; and Nicholas Lucente, US Product Lead, Secondary Stroke Prevention, Bayer.

“Congratulations to this year’s VITAL Award honorees. Your work demonstrates that meaningful progress in life sciences is driven by leaders who combine bold thinking with the determination to turn ideas into measurable impact. We are proud to recognize your contributions and the example you have set for the industry,” said Manish Gupta, Chairman and CEO, Indegene

Indegene Digital Summit is Indegene's flagship thought leadership platform for the life sciences industry, facilitating dialogue among senior executives, regulators, and digital innovators. A #FutureReadyHealthcare initiative, the Summit is orchestrated by Indegene. For updates, follow #FutureReadyHealthcare on LinkedIn.

For session recordings, summaries, and more, visit: <https://digitalsummit.indegene.com/>

About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is the strategic operating partner to the life sciences industry, orchestrating commercial, medical, R&D, and safety operations across the product lifecycle. Trusted by the world's top 20 biopharma companies, Indegene helps run complex, highly regulated workflows at global scale.

Indegene combines deep life sciences expertise with AI-embedded platforms and governed operating models to improve speed, consistency, and compliance across mission-critical operations. By integrating technology into how work is executed and scaled, Indegene enables life sciences organizations to deliver measurable outcomes in regulated environments.

For more information, visit www.indegene.com.